XML 68 R57.htm IDEA: XBRL DOCUMENT
v3.23.1

In-licensing Agreements - Additional Information (Details) | 1 Months Ended | 3 Months Ended |
--- | --- | --- | ---
Aug. 31, 2022 License | Mar. 31, 2017 USD ($) | Mar. 31, 2023 USD ($) | Mar. 31, 2022 USD ($) | Aug. 31, 2016 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |
Research and development expense |  |  | $ 92,861,000 | $ 107,649,000 |
Eidos Therapeutics, Inc | Stanford License Agreement | Leland Stanford Junior University |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |
License fees |  | $ 10,000 |  |  |
Milestone payments |  |  |  |  | $ 1,000,000.0
License agreement of percentage |  |  | 10.00% |  |
TheRas, Inc | Leidos Biomedical Research License and Cooperative Research and Development Agreements | Leidos Biomedical Research, Inc |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |
Research and development expense |  |  | $ 500,000 | 400,000 |
Number of license agreements | License | 2 |  |  |  |
QED Therapeutics, Inc | Foundation Medicine Diagnostics Agreement | Foundation Medicine, Inc |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |
Research and development expense |  |  | $ 0 | $ 600,000 |

X
- Definition License agreement of percentage. + References No definition available. + Details
Name: | bbio_LicenseAgreementOfPercentage
Namespace Prefix: | bbio_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition License fees. + References No definition available. + Details
Name: | bbio_LicenseFees
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of license agreements. + References No definition available. + Details
Name: | bbio_NumberOfLicenseAgreements
Namespace Prefix: | bbio_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Potential milestone payments. + References No definition available. + Details
Name: | bbio_PotentialMilestonePayments
Namespace Prefix: | bbio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 912 -SubTopic 730 -Section 25 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | srt_ConsolidatedEntitiesAxis=bbio_EidosTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bbio_StanfordLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=bbio_LelandStanfordJuniorUniversityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidatedEntitiesAxis=bbio_TheRasIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bbio_LeidosBiomedicalResearchLicenseAndCooperativeResearchAndDevelopmentAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=bbio_LeidosBiomedicalResearchIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidatedEntitiesAxis=bbio_QEDTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bbio_FoundationMedicineDiagnosticsAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=bbio_FoundationMedicineIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |